DDInter125 DDInter833
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Asenapine {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Asenapine {u} (Compound) binds {v} (Gene) HTR1A
HTR1A {u} (Gene) is bound by {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Glycerol phenylbutyrate
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Asenapine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Asenapine (Compound) binds HTR1A (Gene) and HTR1A (Gene) is bound by Alverine (Compound) and Alverine (Compound) resembles Glycerol phenylbutyrate (Compound)
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)